tbuckley/cabot-search huggingface dataset:
Dupilumab Reduces Oral Corticosteroid Use and Severe Exacerbations and Improves Lung Function in Patients With Oral Corticosteroid-Dependent Severe Asthma With and Without Comorbid Allergic Rhinitis in the Phase 3 LIBERTY ASTHMA VENTURE Study
Authors: Mario Castro, Jorge Maspero, Lawrence Sher, Klaus Rabe, Thomas Casale, Megan Rice, Marcella Ruddy, Paul Rowe, Yamo Deniz
Journal: Journal of Allergy and Clinical Immunology (2020)
Salmonella-Induced Changes in Immunoregulatory Bacteria and the Impact on Transcriptional Activity of the Foxp3 and Roryt genes in Rat GALT
Authors: Yuliia Bukina, Aleksandr Kamyshnyi, Halyna Koval, Larisa Fedoniuk, Lawrence Dubuske
Journal: Journal of Allergy and Clinical Immunology (2020)
A Behavior-Manipulating Virus Relative as a Source of Adaptive Genes for<i>Drosophila</i>Parasitoids
Authors: Deborah Di Giovanni, David Lepetit, Benjamin Guinet, Bastien Bennetot, Matthieu Boulesteix, Yohann Couté, Olivier Bouchez, Marc Ravallec, Julien Varaldi
Journal: Molecular Biology and Evolution (2020)

Some species of parasitic wasps have domesticated viral machineries to deliver immunosuppressive factors to their hosts. Up to now, all described cases fall into the Ichneumonoidea superfamily, which only represents around 10% of hymenoptera diversity, raising the question of whether such domestication occurred outside this clade. Furthermore, the biology of the ancestral donor viruses is completely unknown. Since the 1980s, we know that Drosophila parasitoids belonging to the Leptopilina genus, which diverged from the Ichneumonoidea superfamily 225 Ma, do produce immunosuppressive virus-like structure in their reproductive apparatus. However, the viral origin of these structures has been the subject of debate. In this article, we provide genomic and experimental evidence that those structures do derive from an ancestral virus endogenization event. Interestingly, its close relatives induce a behavior manipulation in present-day wasps. Thus, we conclude that virus domestication is more prevalent than previously thought and that behavior manipulation may have been instrumental in the birth of such associations.
Safety Profile of High IgPro20 Infusion Parameters in Patients with Primary Immunodeficiency (PID): Results from The Forced Upward Titration HILO Study
Authors: Mikhail Rojavin, Chengping Hu, John Anderson, Vincent Bonagura, Juthaporn Cowan, Patricia Lugar, Paul Maglione, Shahzad Mustafa, Niraj Patel, John Routes, Panida Sriaroon, Donald VINH, Jutta Hofmann
Journal: Journal of Allergy and Clinical Immunology (2020)
The IL-4Ra R576 polymorphism is associated with increased AD severity and promotes allergic skin inflammation.
Authors: Juan-Manuel Leyva-Castillo, Michelle Daya, Meher Preethi Boorgula, Rasika Mathias, Kathleen Barnes, Peggy Lai, Carter Petty, Eddie Weller, Hani Harb, Talal Chatila, Donald Leung, Wanda Phipatanakul, Raif Geha
Journal: Journal of Allergy and Clinical Immunology (2020)
Evaluation of cytokine levels using QuantiFERON-TB Gold Plus in patients with active tuberculosis
Authors: Maho Suzukawa, Keita Takeda, Shunsuke Akashi, Isao Asari, Masahiro Kawashima, Nobuharu Ohshima, Eri Inoue, Ryota Sato, Masahiro Shimada, Junko Suzuki, Akira Yamane, Atsuhisa Tamura, Ken Ohta, Shigeto Tohma, Katsuji Teruya, Hideaki Nagai
Journal: Journal of Infection (2020)
Abstract 14770: Long Non-Coding RNA NEAT1 Modulates Angiogenic and Proliferative Capacity of Endothelial Cells
Authors: Alisha V Haug, Astrid Werner, Andreas M Zeiher, Stefanie Dimmeler
Journal: Circulation (2018)

Non-coding RNAs are increasingly recognized as regulators of various biological functions. Specifically, long non-coding RNAs (lncRNAs) are known to control epigenetic, transcriptional and post-tra...
Postpartum Involution and Cancer: An Opportunity for Targeted Breast Cancer Prevention and Treatments?
Authors: Virginia F. Borges, Traci R. Lyons, Doris Germain, Pepper Schedin
Journal: Cancer Research (2020)

Childbirth at any age confers a transient increased risk for breast cancer in the first decade postpartum and this window of adverse effect extends over two decades in women with late-age first childbirth (>35 years of age). Crossover to the protective effect of pregnancy is dependent on age at first pregnancy, with young mothers receiving the most benefit. Furthermore, breast cancer diagnosis during the 5- to 10-year postpartum window associates with high risk for subsequent metastatic disease. Notably, lactation has been shown to be protective against breast cancer incidence overall, with varying degrees of protection by race, multiparity, and lifetime duration of lactation. An effect for lactation on breast cancer outcome after diagnosis has not been described. We discuss the most recent data and mechanistic insights underlying these epidemiologic findings. Postpartum involution of the breast has been identified as a key mediator of the increased risk for metastasis in women diagnosed within 5-10 years of a completed pregnancy. During breast involution, immune avoidance, increased lymphatic network, extracellular matrix remodeling, and increased seeding to the liver and lymph node work as interconnected pathways, leading to the adverse effect of a postpartum diagnosis. We al discuss a novel mechanism underlying the protective effect of breastfeeding. Collectively, these mechanistic insights offer potential therapeutic avenues for the prevention and/or improved treatment of postpartum breast cancer.
Positive follow-up blood cultures identify high mortality risk among patients with Gram-negative bacteraemia
Authors: S.A. Maskarinec, L.P. Park, F. Ruffin, N.A. Turner, N. Patel, E.M. Eichenberger, D. van Duin, T. Lodise, V.G. Fowler, J.T. Thaden
Journal: Clinical Microbiology and Infection (2020)
Tidal volume and helmet: Is the never ending story coming to an end?
Authors: A. Cortegiani, M. Ippolito, M. Luján, C. Gregoretti
Journal: Pulmonology (2020)

Noninvasive ventilation (NIV) has been increasingly used in acute care setting with various indications 1---3,4 but its use in patients with acute hypoxemic respiratory failure (AHRF) is controversial. 5,6,7lthough spontaneous patient activity during mechanical ventilation (MV) may reduce the likelihood of ventilationperfusion mismatch, especially in dependent regions, close to the diaphragm, high transmural vascular and transpulmonary pressure swing may worsen vascular leakage and increase tidal volume (V t ), leading to self-inflicted lung injury (SILI). 8From the clinical side, expiratory V t of 6 mL/kg used in invasive MV during lung protective ventilation 1 is almost impossible to achieve in most of the patients receiving NIV for AHRF.This is particularly important in de novo AHRF patients undergoing NIV, 1,2 since large expiratory V t may be generated 9,10 in assisted pressure controlled modes by the ventilator pressure and by the respiratory muscles.
样肉芽肿和 Sézary 综合征患者生活质量研究
Authors: K. Molloy, C. Jonak, F.J. Sherida, H. Woei‐A‐Ji, E. Guenova, A.M. Busschots, A. Bervoets, E. Hauben, R. Knobler, S. Porkert, C. Fassnacht, R. Cowan, E. Papadavid, M. Beylot‐Barry, E. Berti, S. Alberti Violetti, T. Estrach, R. Matin, O. Akilov, L. Vakeva, M. Prince, A. Bates, M. Bayne, R. Wachsmuch, U. Wehkamp, M. Marschalko, O. Servitje, D. Turner, S. Weatherhead, M. Wobser, J.A. Sanches, P. McKay, D. Klemke, C. Peng, A. Howles, J. Yoo, F. Evison, J. Scarisbrick
Journal: British Journal of Dermatology (2020)

蕈样肉芽肿 (MF) 是最常见的皮肤淋巴瘤类型,属于皮肤 T 细胞淋巴瘤 (CTCL) 一类疾病。MF 可表现为扁平/凸起、光滑/鳞状红色病变,称为斑片和斑块,因此难以与湿疹或银屑病相鉴别。可能会出现被称为肿瘤的凸起“肿块”,并且疾病可能变得更加严重。 Sézary 综合征 (SS) 是 CTCL 的一种白血病形式,在全身大多数部位出现广泛的红色瘙痒性皮疹,血液中存在癌细胞,淋巴结肿大。 因为瘙痒和疼痛等症状、因外观缺陷继发的自尊心受挫,MF/SS 可降低患者的生活质量 (QoL),并可损害人际关系。在本文中,我们使用称为 Skindex-29 的一项大型国际研究 PROCLIPI 调查了 MF/SS 患者的 QoL,该问卷请患者对可能影响其生活享受的皮肤相关问题发表评论。 我们发现 MF/SS 中生活质量较差的很多重要决定因素包括:女性、诊断为 SS 的患者和更广泛的疾病患者。与 QoL 下降更多相关的疾病特征包括脱发(掉头发)和融合性红斑(红斑和斑块融合形成更大的受累皮肤区域)。综合所有这些因素,我们发现女性患者、脱发和融合性红斑是最重要的。 考虑到女性 QoL 更差,我们更加仔细地研究了 Skindex-29 调查问卷中男性和女性之间哪些项目有所不同。女性患者有更多的皮肤灼痛、刺痛、瘙痒和刺激感,以及在诊断为 MF/SS 时有更多的抑郁、羞耻、尴尬和烦恼的感觉。 我们的研究强调了 MF/SS 中 QoL 的重要方面,并强调了迫切需要更全面的 QoL 调查问卷,不仅针对疾病的皮肤相关方面,而且涵盖癌症及其治疗对患者 QoL 的影响。 本摘要涉及研究: 前瞻性皮肤淋巴瘤国际预后指数 (PROCLIPI) 研究发现的与蕈样肉芽肿/Sézary 综合征患者生活质量明显更差相关的特征
Oral brincidofovir decreases the incidence of HHV-6B viremia after allogeneic HCT
Authors: Joshua A. Hill, W. Garrett Nichols, Francisco M. Marty, Genovefa A. Papanicolaou, Thomas M. Brundage, Randall Lanier, Danielle M. Zerr, Michael J. Boeckh
Journal: Blood (2020)
Association of Depression, Anxiety, and Trauma With Cannabis Use During Pregnancy
Authors: Kelly C. Young-Wolff, Varada Sarovar, Lue-Yen Tucker, Nancy C. Goler, Stacey E. Alexeeff, Kathryn K. Ridout, Lyndsay A. Avalos
Journal: JAMA Network Open (2020)

has been shown to be safe. 6Pregnant women should be screened for cannabis use, asked about their reasons for use, educated about potential risks, and advised to quit.Furthermore, early screening for prenatal depression, anxiety, and trauma, and linkage to appropriate interventions might mitigate the risk of prenatal cannabis use.
Prevalence of pathogenic germline risk variants (PVs) in 1,829 renal cell carcinoma (RCC) patients (pts).
Authors: Sarah Abou Alaiwi, Amin Nassar, Elio Adib, Elie Akl, Stefan Groha, Edward D. Esplin, Sarah Nielsen, Shan Yang, Bradley Alexander McGregor, Mark Pomerantz, Alexander Gusev, Huma Q. Rana, Guru Sonpavde, Judy Ellen Garber, Matthew L. Freedman, Toni K. Choueiri
Journal: Journal of Clinical Oncology (2020)

659 Background: Hereditary RCCs account for 3-5% of all RCC cases. The prevalence and significance of germline PVs of RCC have not been fully characterized. Methods: We evaluated the frequency of pathogenic and likely pathogenic variants, referred to as PVs, in 1829 high-risk RCC pts who underwent targeted clinical germline testing (1-134 genes) at a commercial laboratory. PVs, including single nucleotide variants/indels/ copy number variants, were confirmed using orthogonal technology in accordance with Invitae’s standard operating practices. Actionable genes were defined as established cancer-predisposition genes that confer a higher risk for any cancer phenotype and for which enhanced screening and family genetic testing are recommended by the National Comprehensive Cancer Network. We focused our analysis on genes tested in more than 100 pts (n=93). Results: Among 1892 pts, 54.9% were male, and 68.9% were Caucasians, with median age 50 (range:1-87) years at RCC diagnosis. 11.8% (n=215) of pts had at least 2 primary RCCs, and 30.7% (n= 561) had a personal history of another cancer. The cumulative frequency of pts with PVs was 17.7%. PVs in known RCC susceptibility genes such as FH, FLCN, and SDHB were detected in 1.8% (29/1622), 1.22% (120/1634) and 0.64% (11/1727) of pts respectively. PVs in other cancer-associated genes were most frequently reported in CHEK2 (loss-of-function variants, 30/1276, 2.4%), MUTYH (19/1124, 1.7%), and BRCA2 (17/1276, 1.33%). PVs in DNA-damage repair genes (DRG) accounted for 71.8% of PVs and, overall, were detected in 12.7% of pts. Among the DRG, PVs in the homologous recombination pathway (ATM, BARD1, BLM, BRCA1, BRCA2, BRIP1, CHEK2, NBN, PALB2, RECQL4, WRN) were the most prevalent (7.8%) whereas the mismatch repair pathway (MLH1, MSH2, MSH6, PMS2) was altered in only 0.7% of pts. Of the examined cohort, 9.7% of pts had ≥1 actionable PV. In non-Caucasians, BRCA2 PVs were the most common (6/273, 2.20%). Conclusions: PVs were identified in 17.7% of RCC subjects, most of which (71.8%) were in DRG, with »10% of pts having actionable variants. Our work is concordant with known RCC susceptibility genes and potentially highlights novel risk genes that should be validated in future studies.
(NZW×BXSB)F1マウス 自然発生的血小板減少性紫斑病の新しい動物モデル
Authors: Oyaizu N, Yasumizu R, Miyama‐Inaba M, Nomura S, Miyawaki S, Mitsuoka S, Morii S, Good R A, Ikehara S
Journal: The Journal of Experimental Medicine (1988)
Abstract 14813: Insomnia, Sleep Duration and Risk of Heart Failure Among Post-menopausal Women: The Women's Health Initiative
Authors: Amr El Meligy, Mohammad Khan, Somwail Rasla, Mary B Roberts, Aladdin H Shadyab, Matthew Allison, Michael J Lamonte, Elena Salmoirago-Blotcher, JoAnn E Manson, Lauren Hale, Charles B Eaton
Journal: Circulation (2017)

Introduction: Women report more sleep problems and have a higher prevalence of insomnia than men. Among heart failure (HF) patients, the prevalence of insomnia symptoms ranges from 23% to 73%. Howe...
Adverse Effects of Low-Dose Methotrexate
Authors: Daniel H. Solomon, Robert J. Glynn, Elizabeth W. Karlson, Fengxin Lu, Cassandra Corrigan, Josh Colls, Chang Xu, Jean MacFadyen, Medha Barbhaiya, Nancy Berliner, Paul F. Dellaripa, Brendan M. Everett, Aruna D. Pradhan, Sarah P. Hammond, Meredith Murray, Deepak A. Rao, Susan Y. Ritter, Anna Rutherford, Jeffrey A. Sparks, Jackie Stratton, Dong H. Suh, Sara K. Tedeschi, Kathleen M.M. Vanni, Nina P. Paynter, Paul M Ridker
Journal: Annals of Internal Medicine (2020)

Background: Low-dose methotrexate (LD-MTX) is the most commonly used drug for systemic rheumatic diseases worldwide and is the recommended first-line agent for rheumatoid arthritis. Despite extensive clinical use for more than 30 years, few data on adverse event (AE) rates derive from randomized, placebo-controlled trials, where both causality and magnitude of risk can be inferred. Objective: To investigate AE rates, risk, and risk differences comparing LD-MTX versus placebo. Design: Prespecified secondary analyses of a double-blind, placebo-controlled, randomized trial. (ClinicalTrials.gov: NCT01594333) Setting: North America. Participants: Adults with known cardiovascular disease and diabetes or metabolic syndrome. Intervention: Random allocation to LD-MTX (≤20 mg/wk) or placebo. All participants received folic acid, 1 mg/d, 6 days per week. Measurements: Risks for specific AEs of interest, as well as for all AEs, were compared across treatment groups after blinded adjudication. Results: After an active run-in period, 6158 patients were enrolled and 4786 randomly assigned to a group; median follow-up was 23 months and median dosage 15 mg/wk. Among the randomly assigned participants, 81.2% were male, median age was 65.7 years, and median body mass index was 31.5 kg/m2. Of 2391 participants assigned to LD-MTX, 2080 (87.0%) had an AE of interest, compared with 1951 of 2395 (81.5%) assigned to placebo (hazard ratio [HR], 1.17 [95% CI, 1.10 to 1.25]). The relative hazards of gastrointestinal (HR, 1.91 [CI, 1.75 to 2.10]), pulmonary (HR, 1.52 [CI, 1.16 to 1.98]), infectious (HR, 1.15 [CI, 1.01 to 1.30]), and hematologic (HR, 1.15 [CI, 1.07 to 1.23]) AEs were elevated for LD-MTX versus placebo. With the exception of increased risk for skin cancer (HR, 2.05 [CI, 1.28 to 3.28]), the treatment groups did not differ in risk for other cancer or mucocutaneous, neuropsychiatric, or musculoskeletal AEs. Renal AEs were reduced in the LD-MTX group (HR, 0.85 [CI, 0.78 to 0.93]). Limitation: The trial was done in patients without rheumatic disease who tolerated LD-MTX during an active run-in period. Conclusion: Use of LD-MTX was associated with small to moderate elevations in risks for skin cancer and gastrointestinal, infectious, pulmonary, and hematologic AEs, whereas renal AEs were decreased. Primary Funding Source: National Institutes of Health.
Association of Asthma Prognosis with Risk of Asthma-Associated Infectious and Inflammatory Multimorbidities (AIMs) in Children with Asthma
Authors: Jung Kwon, Euijung Ryu, Chung-Il Wi, HeeYun Seol, Katherine King, Jungwon Yoon, Miguel Park, Sunghwan Sohn, Hongfang Liu, Young Juhn
Journal: Journal of Allergy and Clinical Immunology (2020)
PAX1 is essential for development and function of the human thymus
Authors: Yasuhiro Yamazaki, Raul Urrutia, Luis M. Franco, Silvia Giliani, Kejian Zhang, Anas M. Alazami, A. Kerry Dobbs, Stefania Masneri, Avni Joshi, Francisco Otaizo-Carrasquero, Timothy G. Myers, Sundar Ganesan, Maria Pia Bondioni, Mai Lan Ho, Catherine Marks, Huda Alajlan, Reem W. Mohammed, Fanggeng Zou, C. Alexander Valencia, Alexandra H. Filipovich, Fabio Facchetti, Bertrand Boisson, Chiara Azzari, Bander K. Al-Saud, Hamoud Al-Mousa, Jean Laurent Casanova, Roshini S. Abraham, Luigi D. Notarangelo
Journal: Science Immunology (2020)

We investigated the molecular and cellular basis of severe combined immunodeficiency (SCID) in six patients with otofaciocervical syndrome type 2 who failed to attain T cell reconstitution after allogeneic hematopoietic stem cell transplantation, despite successful engraftment in three of them. We identified rare biallelic PAX1 rare variants in all patients. We demonstrated that these mutant PAX1 proteins have an altered conformation and flexibility of the paired box domain and reduced transcriptional activity. We generated patient-derived induced pluripotent stem cells and differentiated them into thymic epithelial progenitor cells and found that they have an altered transcriptional profile, including for genes involved in the development of the thymus and other tissues derived from pharyngeal pouches. These results identify biallelic, loss-of-function PAX1 mutations as the cause of a syndromic form of SCID due to altered thymus development.
Bad Gene Hunting—Sudden Unexplained Death and Familial Long QT Syndrome
Authors: Katharine A. Wallis
Journal: JAMA Cardiology (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Cardiology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Cardiology journal
Study EV-103: New cohorts testing enfortumab vedotin alone or in combination with pembrolizumab in muscle invasive urothelial cancer.
Authors: Christopher J. Hoimes, Jonathan E. Rosenberg, Daniel Peter Petrylak, Anne-Sophie Carret, Carolyn Sasse, Marya F. Chaney, Thomas W. Flaig
Journal: Journal of Clinical Oncology (2020)

TPS595 Background: Neoadjuvant cisplatin-based chemotherapy is standard of care for muscle invasive urothelial cancer (MIUC) before radical cystectomy (RC) and lymph node dissection in cisplatin-eligible patients (pts). However, many pts are cisplatin-ineligible and while PD-1/PD-L1 inhibitors have had encouraging results in this population, they are not approved for MIUC; new therapies are needed. Enfortumab vedotin (EV), an investigational antibody-drug conjugate, delivers the microtubule-disrupting agent monomethyl auristatin E to cells expressing Nectin-4, which is highly expressed in urothelial cancer. In a phase 2 study, EV monotherapy had a confirmed ORR of 44% in 125 heavily pre-treated metastatic urothelial cancer (mUC) pts (Rosenberg JCO 2019). In the present study, an initial analysis of EV combined with the PD-1 inhibitor, pembrolizumab (P) had a confirmed ORR of 71% in 45 cisplatin-ineligible mUC pts in the first-line setting (Hoimes ESMO 2019). These results suggest that EV and EV+P may be suitable for research in MIUC. Methods: Study EV-103 (NCT03288545) mUC cohorts were described previously (Hoimes ASCO 2019). Sequential cohorts were added to test EV alone (Cohort H, n = 20) and EV+P (Cohort J, n = 20) as neoadjuvant therapy in cisplatin-ineligible pts (stage cT2-T4a, N0, M0) with treatment naive MIUC. Eligible pts are ECOG 0-2, have CrCl ≥30 mL/min, and are medically fit for and scheduled for RC. Cohort H pts receive 3 cycles of EV (1.25 mg/kg) on Days 1 and 8 of each 3-week cycle. Cohort J pts receive 3 cycles of EV as described for Cohort H plus P on Day 1 of each cycle. Following EV or EV+P, pts undergo their scheduled RC. Pathological complete response (pCR) rate per local pathology review is the primary endpoint of the MIUC cohorts. Secondary endpoints include assessment of pCR and pathological response (PaR) rate per central pathology review, PaR per local pathology review, PFS and investigator assessed disease-free survival per RECIST v1.1, OS, and assessment of safety and tolerability, including planned surgeries delayed due to treatment-related adverse events. The ongoing study opened Oct 2017 and was amended to include MIUC cohorts Aug 2019. Clinical trial information: NCT03288545.
Biomarkers for Clinical Outcome of Combined Immunotherapy with Granulocyte-Macrophage Colony-Stimulating Factor-Tranduced Allogeneic Prostate Cancer Cells (GVAX) and Ipilimumab in Castration-Resistant Prostate Cancer Patients (CRPC)
Authors: W.R. Gerritsen, S. Santegoets, A. Stam, K. Hege, J. Versluis, N. Sacks, I. Lowy, T. Harding, A. van den Eertwegh, T. De Gruijl
Journal: Annals of Oncology (2012)
Any regression of tumor (ART) within 12 weeks versus RECIST 1.1 response category as an intermediate endpoint to assess the activity of immune checkpoint inhibitors (ICIs) for metastatic urothelial carcinoma (mUC).
Authors: Catherine Curran, Gregory Russell Pond, Amin Nassar, Sarah Abou Alaiwi, Bradley Alexander McGregor, Kerry L. Kilbridge, Guru Sonpavde
Journal: Journal of Clinical Oncology (2020)

473 Background: Many ICIs are approved to treat mUC following platinum-based chemo and as 1st-line therapy for selected patients (pts). While RECIST 1.1 responses are generally durable and associated with prolonged survival, the benefit of ICIs extends beyond this group of pts. Stable disease (SD) consists of a heterogeneous population of pts with both increase and decrease in tumor size and is confounded by the impact of pre-ICI disease pace. We hypothesized that in the setting of ICIs, any regression of tumor (ART) within 12 weeks may capture early benefit and correlate with survival more comprehensively than RECIST 1.1. Methods: mUC pts who received an ICI following platinum-based chemo at DFCI were eligible for analysis. Pts were required to have tumor size changes, RECIST 1.1 response by week 12 and survival data available. Demographics and prognostic factors were collected. Descriptive stats were calculated, and univariable Cox proportional hazards regression analysis was conducted to examine the prognostic effect of ART and RECIST 1.1 with overall survival (OS). Results: 104 pts were evaluable. The median age was 66 (range 34-89). 71% were male. The numbers of pts with ART and RECIST1.1 partial response (PR) were 45 (43.3%) and 32 (30.1%), respectively. Univariable analyses identified an association between ART and RECIST 1.1 response with OS (p&lt;0.001). The 1-year OS (95% CI) for ART vs. no ART was 83.6 % (68.7, 91.8) and 35.9 % (23.1, 48.8), while the 1-year OS (95% CI) for RECIST 1.1 response vs. no response was 81.3% (62.9, 91.1) and 45.6% (32.9, 57.4), respectively. RECIST 1.1 category was not significantly associated with OS (p-value=0.68) after adjusting for ART; however, statistically, ART associated with OS (p=0.002) after adjusting for RECIST 1.1 category. The modest size of this cohort is a limitation. Conclusions: ART within 12 weeks is identified early and is robustly associated with OS in pts with mUC receiving post-platinum ICIs. ART may serve as a more optimal intermediate endpoint for survival compared to RECIST 1.1 in the setting of ICIs. Evaluating this endpoint in other malignancies is warranted.